Oncology

Functional MRI biomarkers supporting oncology trials, including diffusion, DCE-MRI, and hypoxia imaging.

Tumour hypoxia imaging map
Oxygen-enhanced MRI can map tumour hypoxia and therapy response.

Bioxydyn provides advanced functional MRI biomarkers in oncology, using techniques such as diffusion MRI and dynamic contrast-enhanced (DCE) MRI. We are a leading CRO offering tumour hypoxia imaging to inform therapy effectiveness and characterise tumour physiology.

We are world-leading in the use of oxygen-enhanced MRI (OE-MRI), which can be applied to monitor the delivery of oxygen to tumours. Tumour oxygenation levels impact disease progression and response to therapy, and our methods for identifying hypoxia are sensitive to drug and radiotherapy effects.

Parametric tumour hypoxia map
Parametric hypoxia maps derived from OE-MRI (example).

Dynamic contrast-enhanced MRI is recognised by the Quantitative Imaging Biomarkers Alliance (QIBA) as a biomarker of angiogenesis and vascular function in cancer. Bioxydyn personnel bring decades of experience to the study of cancer using DCE-MRI.

Diffusion MRI, using the apparent diffusion coefficient (ADC), detects changes in water diffusion and can act as an early marker of biological response to treatment. These measurements support sensitive, repeatable imaging endpoints in oncology trials.

Oncology publications

Peer-reviewed oncology imaging studies led by Bioxydyn teams, with key publications highlighted.

6 publications Refine by area, year, or keyword.
  • Combined oxygen-enhanced MRI and perfusion imaging detect hypoxia modification from banoxantrone and atovaquone and track their differential mechanisms of action
    2024 Research Article
    Key Publication

    Combined oxygen-enhanced MRI and perfusion imaging detect hypoxia modification from banoxantrone and atovaquone and track their differential mechanisms of action

    O'Connor JPB, Tessyman V, Little RA, Babur M, Forster D, Latif A, et al.

    Cancer Res Commun 4(10):2565-2574

    Why it matters: Shows hypoxia modulation tracking with combined OE-MRI and perfusion imaging.

    Oncology
  • Oxygen-enhanced MRI detects incidence, onset and heterogeneity of radiation-induced hypoxia modification in HPV-associated oropharyngeal cancer
    2024 Research Article

    Oxygen-enhanced MRI detects incidence, onset and heterogeneity of radiation-induced hypoxia modification in HPV-associated oropharyngeal cancer

    Dubec MJ, Price J, Berks M, Gaffney J, Little RA, Porta N, et al.

    Clin Cancer Res

    Oncology
  • Measuring repeatability of dynamic contrast-enhanced MRI biomarkers improves evaluation of biological response to radiotherapy in lung cancer
    2024 Research Article

    Measuring repeatability of dynamic contrast-enhanced MRI biomarkers improves evaluation of biological response to radiotherapy in lung cancer

    Sridharan N, Salem A, Little RA, Tariq M, Cheung S, Dubec MJ, et al.

    Eur Radiol

    OncologyRespiratory
  • First-in-human technique translation of oxygen-enhanced MRI to an MR Linac system in patients with head and neck cancer
    2023 Research Article

    First-in-human technique translation of oxygen-enhanced MRI to an MR Linac system in patients with head and neck cancer

    Dubec MJ, Buckley DL, Berks M, Clough A, Gaffney J, Datta A, et al.

    Radiother Oncol 183:109592

    Oncology
  • Oxygen-enhanced MRI is feasible, repeatable, and detects radiotherapy-induced change in hypoxia in xenograft models and in patients with non-small cell lung cancer
    2019 Research Article

    Oxygen-enhanced MRI is feasible, repeatable, and detects radiotherapy-induced change in hypoxia in xenograft models and in patients with non-small cell lung cancer

    Salem A, Little RA, Latif A, Featherstone AK, Babur M, Peset I, et al.

    Clin Cancer Res 25(13):3818-3829

    OncologyRespiratory
  • 2018 Research Article

    Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer

    Jayson GC, Zhou C, Backen A, Horsley L, Marti-Marti K, Shaw D, et al.

    Nat Commun 9(1):4672

    Oncology
    DOI PubMed
Website built by Bioxydyn. We can build software for you - get in touch.